We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 5 for:    inmune bio [Lead]

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05321498
Recruitment Status : Not yet recruiting
First Posted : April 11, 2022
Last Update Posted : August 17, 2022
Sponsor:
Information provided by (Responsible Party):
Inmune Bio, Inc.

Brief Summary:
The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with neuroinflammation (APOE4) and to evaluate safety, tolerability, and efficacy of XPro1595.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment (MCI) Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Mental Disorders Drug: XPro1595 Drug: Placebo Phase 2

Detailed Description:
This study is designed as a Phase 2, double-blind randomized, placebo-controlled study investigating the safety, tolerability, and efficacy of XPro1595 in patients with MCI. The planned dose is 1.0 mg/kg of XPro1595 and matching placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
  • (2:1) XPro1595 (1mg/kg), placebo
  • Weekly subcutaneous injections
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation
Estimated Study Start Date : September 2022
Estimated Primary Completion Date : January 26, 2023
Estimated Study Completion Date : January 26, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1.0 mg/kg XPro1595
1.0 mg/kg XPro1595 will be administered via subcutaneous injection once a week for 12 weeks.
Drug: XPro1595
XPro1595 will be delivered by subcutaneous injection once a week.
Other Names:
  • INB03/XPro™
  • XENP1595
  • Dominant-negative Tumor Necrosis Factor (DN-TNF)

Placebo Comparator: 1.0 mg/kg Placebo
1.0 mg/kg of Placebo will be administered via subcutaneous injection once a week for 12 weeks.
Drug: Placebo
Placebo will be delivered by subcutaneous injection once a week
Other Name: Matching Placebo




Primary Outcome Measures :
  1. Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) [ Time Frame: 12 Weeks ]

    Change from Baseline to Week 12 in the Early and Mild Alzheimer's Cognitive Composite (EMACC) (Jaeger 2017) made up of the following tests:

    • International Shopping List Test- Immediate recall (Word List Learning Test-Immediate recall)
    • Trail Making Test Part A and B
    • Digit Symbol Coding Test
    • Digit Span Forward and Backward
    • Category Fluency Test (DKEFS)
    • Letter Fluency Test (DKEFS)

    To assess the efficacy of XPro1595 compared with placebo on cognitive performance in patients with MCI



Secondary Outcome Measures :
  1. Change in Mean Computer-based Cognitive Assessment (Cogstate) Composite score from Screening to Week 12 [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in Cogstate Composite mean score.

    Cogstate is a brief, computerized, neuropsychological battery to evaluate cognitive impairments in mild cognitive impairment (MCI), and Alzheimer's disease (AD). CogState assesses attention and memory functions - including Information processing speed, Visual attention, Working memory and Visual learning. Cogstate scores are measured on a linear scale (with no maximum score). A reduction in scores compared to baseline signifies an improvement in cognitive functions.

    The Cogstate battery will be administered at Screening and each week for 12 weeks.

    To assess the efficacy of XPro1595 compared with placebo on cognitive performance in patients with MCI


  2. Change in myelin content [ Time Frame: 12 Weeks ]
    Change from Screening to Week 12 in myelin content.

  3. Change in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid) [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid)

    To assess the efficacy of XPro1595 compared with placebo on blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid)


  4. Change in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau) [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau)

    To assess the efficacy of XPro1595 compared with placebo on blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau)


  5. Change in Imaging (MRI) Neuroinflammation [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in MRI neuroinflammation (White matter Free Water)

    To assess the efficacy of XPro1595 compared with placebo on imaging neuroinflammation


  6. Change in imaging markers of brain quality [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in regional brain glucose uptake as measured by F-fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) scans

    Alzheimer's Disease (AD) is characterized by a chronic brain glucose deficit. White matter glucose deterioration is also evident in Mild Cognitive Impairment (MCI) and specific to limbic fascicles. We will quantify the change in regional brain glucose uptake for gray matter and white matter tracts using PET imaging and the F-fluorodeoxyglucose (FDG) radiotracer. PET maps will be registered to Magnetic Resonance (MR) anatomical images and corrected for partial volume effect. Standard uptake value ratios (SUVr) will be calculated using the cerebellum as a reference region.

    FDG-PET scans will be performed at Screening and Week 12.

    To assess the efficacy of XPro1595 compared with placebo on imaging markers of brain quality


  7. Change in apparent fiber density (AFD) [ Time Frame: 12 Weeks ]

    Change from Baseline to Week 12 in MRI Apparent Fiber Density (AFD)

    To assess the efficacy of XPro1595 compared with placebo on axonal integrity in patients with MCI


  8. Change in non-cognitive behavioral symptoms [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in Neuropsychiatric Inventory (NPI-12) study partner items

    To assess the effect of XPro1595 compared with placebo on non-cognitive behavioral symptoms in patients with MCI


  9. Change in brain activity [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in brain activity as measured by electroencephalogram (EEG) scans (Change in brain activity as measured by the EEG in microvolts).

    Specifically, a series of EEG markers previously associated with AD (Horvath et al. 2018) including high and low frequency band powers, the P300, and Mismatch Negativity (MMN) event-related potentials will be evaluated.

    An EEG scan will be administered at Screening and each week for 12 weeks.

    To assess the efficacy of XPro1595 compared with placebo on brain activity in patients with MCI


  10. Change in speech and language [ Time Frame: 12 Weeks ]

    Change from Baseline to Week 12 in language and speech patterns using Winterlight Labs analysis

    To assess the effect of XPro1595 compared with placebo on speech and language in patients with MCI


  11. Change in Alzheimer's Disease Cooperative Study - Mild Cognitive Impairment Activities of Daily Living (ADCS-MCI ADL) [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in Alzheimer's Disease Cooperative Study - Mild Cognitive Impairment Activities of Daily Living (ADCS-MCI ADL)

    The 23-item ADCS-MCI-ADL Scale has good test-retest reliability, will be utilized to assess performance functioning in MCI patients (Galasko et al., 1997; Douglas Galasko et al., 2006; Pedrosa et al., 2010). The ADCS-ADL includes 18 items from traditional basic ADL scales and 5 items from instrumental activities of daily living scales (IADL) The possible range of total scores for the ADL Scale is 0-53 and higher scores indicate better functioning. The internal reliability was .91( Galasko et al., 1997; Douglas Galasko et al., 2006; Pedrosa et al., 2010).

    The ADCS-MCI ADL will be performed at Screening and Week 12.

    To assess the effect of XPro1595 compared with placebo on Activities of Daily Living (ADL) in patients with MCI


  12. Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

    The CDR scale is a clinician-rated dementia staging system that tracks the progression of cognitive impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5-point scale in which None = 0, Questionable = 0.5, Mild = 1, Moderate = 2, and Severe = 3. The global CDR score is established by clinical scoring rules and has values of 0 (no dementia), 0.5, (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is obtained by adding the ratings in each of the 6 categories and ranges from 0 to 18 with higher scores indicative of greater impairment.

    To assess the effect of XPro1595 compared with placebo on cognition and global function in patients with MCI


  13. Number of participants who experience adverse events and serious adverse events [ Time Frame: Screening up to 28 days post last dose ]
    Clinically significant abnormalities of laboratory values, physical findings, electrocardiogram findings and other safety assessments will be recorded as adverse events if the findings meet the defined criteria for adverse events.


Other Outcome Measures:
  1. Change in Goal Attainment Scale (GAS) [ Time Frame: 12 Weeks ]

    Change in Goal Attainment Scale (GAS)

    The achievement of each goal is rated on a 5-point attainment scale (-2, -1, 0, +1, +2) to allow standardized scoring of personalized outcomes. A participant's overall goal attainment is quantified using a formula that takes into account the number of goals that have been set, and the extent to which they are correlated with each other. For each identified goal area, the caregiver will be asked to give a detailed description of the patient's current (baseline) status and goal status, which will be recorded at the -1 and 0 levels on the 5-point scale, respectively. The remaining levels of the scale will then be set: somewhat better than the goal (+1), much better than the goal (+2), and much worse than the goal (-2).

    To evaluate the effect of XPro1595 compared with placebo on goal attainment scores


  2. Change in measures of activity [ Time Frame: 12 Weeks ]

    Change from Screening to Week 12 in activity metrics (time spent lying, sitting, standing, stepping, upright, in walking bouts, in context specific walking bouts; number of steps, and sit-to-stand transitions) as measured by the activPAL monitor. Physical activity will be measured in real time using the activPal accelerometer worn on the patient's thigh. Total activity counts per minute (higher activity counts = more activity) and number of steps taken will be derived from data. Types of activity (e.g., sitting versus standing) are determined through activPAL's proprietary algorithms. Patients will be equipped with the activPAL and activity metrics will be measured prior to each EMACC assessment. Data will be measured at Screening, Week 1, Week 3, Week 6, Week 9 and Week 12.

    To assess the effect of XPro1595 compared to placebo on measures of activity


  3. Evaluate predictability of patient response after placebo administration and potential influence of study partners on outcome evaluation using the Multidimensional Psychological Questionnaire (MPsQ) with a 5 point scale [ Time Frame: 12 Weeks ]

    The Multidimensional Psychological Questionnaire (MPsQ) questionnaires have been designed to specifically measure patient personality characteristics associated with the placebo response. The MPsQ questionnaires are self-reported, and each item is rated on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree).

    MPsQs will be completed by the patient and separate MPsQs will be completed by the study partner at screening.

    MPsQs will be completed by the patient and separate MPsQs will be completed by the study partner prior to investigational product administration.

    The patient and study partner will complete MPsQs at Screening and Week 1.

    To measure patient personality characteristics associated with the placebo response.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients are eligible to be included in the study only if all the following criteria apply:

  • Adult male and female patients ≥ 55 years to ≤ 80 years of age at the time of consent;
  • Diagnosed with MCI of probable Alzheimer's disease (Albert 2011; National Institute on Aging - Alzheimer's Association [NIA-AA]). Patients who have received previous therapy for Alzheimer's disease may still be eligible;
  • Amyloid positive (documented in medical history or assessed during screening through blood test);
  • Literate and capable of reading, writing, and communicating effectively with others, based on the PI's assessment;
  • Has a study partner willing to participate for the duration of the trial who either lives in the same household or interacts with the patient at least 4 hours per day and on at least 4 days per week, who is knowledgeable about the patient's daytime and night-time behaviors and who can be available to attend all clinic visits in person at which informant assessments are performed.

Exclusion Criteria:

  • Have any contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in-skull and cardiac devices other than those approved as safe for use in MRI scanners at the strength required for this study);
  • Receives considerable help to carry out basic ADL living either in the home or as a resident in a nursing home or similar facility;
  • Lifetime history of a major psychiatric disorder including schizophrenia and bipolar disorder. Major depressive disorder that has resulted in 2 or more hospitalizations in a lifetime. Major depressive episode during the past 5 years that is judged by the clinical team unlikely to have been part of Alzheimer's prodrome. History of suicidality: has answered "yes" to Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation items 4 or 5, or any suicidal behavior within 6 months before Screening, at Screening, or at the Week 1 Visit, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening;
  • History of substance abuse within 12 months; use of cannabis or cannabis products within 6 months of consent;
  • Enrolled in another clinical trial where patients receive treatment with an investigational drug or treatment device or have received treatment on another AD clinical trial within the last 60 days from Day 1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05321498


Contacts
Layout table for location contacts
Contact: INmune Bio, Inc. (858)964-3720 trials@inmunebio.com

Sponsors and Collaborators
Inmune Bio, Inc.
Investigators
Layout table for investigator information
Study Director: Patricia Hopkins INmune Bio
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Inmune Bio, Inc.
ClinicalTrials.gov Identifier: NCT05321498    
Other Study ID Numbers: XPro1595-AD-03
First Posted: April 11, 2022    Key Record Dates
Last Update Posted: August 17, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Inmune Bio, Inc.:
Inflammation
Biomarker
Tumor Necrosis Factor (TNF)
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Nervous System Diseases
Neurodegenerative Diseases
Brain Diseases
Central Nervous System Diseases
Tauopathies
Inflammation
Cognitive Dysfunction
Mental Disorders
Pathologic Processes
Dementia
Neurocognitive Disorders
Cognition Disorders